Modified vaccinia ankara
- Generic Name
- Modified vaccinia ankara
- Brand Names
- Jynneos
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- TU8J357395
- Background
Modified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus. Vaccines using MVA are live and non-replicating, and are produced using Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN).
- Indication
Modified vaccinia ankara is a vaccine indicated for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection. In the EU, it is additionally indicated for the prevention of other diseases caused by the vaccinia virus.
- Associated Conditions
- Ebola Virus Disease, Monkeypox, Variola Major (Smallpox)
- Associated Therapies
- -
Mpox vaccine is safe and generates a robust antibody response in adolescents
NIH-funded clinical trial of mpox vaccine in adolescents found it safe and generated robust antibody response, similar to adults. Presented at IDWeek2024, interim analysis supports vaccine's safety and immune response in adolescents, crucial for areas with mpox cases.
Which African countries begin roll out Mpox vaccines and what to know about it
Multiple African countries begin mpox vaccine rollout to combat rapid spread; DR Congo most affected with 22,000 infections and 700 deaths; WHO recommends three vaccines: MVA-BN, LC-16, and ACAM2000; vaccines advised for high-risk groups; Rwanda first to roll out vaccines, also battling Marburg virus; WHO monitoring for virus mutations and adjusting strategies as needed.
Unprotected Sex Boosts Mpox Danger for Gay Men as Drug-Resistant Strain Spreads
Unprotected anal sex as the receptive partner increases mpox risk among gay and bisexual men fivefold, according to a CDC study. A second report highlights the spread of a drug-resistant mpox strain in the U.S., emphasizing the need for additional therapeutics. Vaccination with Jynneos remains the most effective prevention method, though vaccine protection wanes within a year.
Bavarian Nordic joins global efforts to fight mpox outbreak in Africa
Bavarian Nordic A/S extends commitment to fight mpox outbreak in Africa with MVA-BN vaccine, approved by US FDA and EMA. Over 9,000 cases and 400 deaths reported in 2024, mostly in DR Congo. DRC grants Emergency Use Authorization for MVA-BN. Bavarian Nordic plans clinical studies for full approval and donates 15,000 doses, collaborating with WHO, UNICEF, and Gavi.
Mpox Vaccine's Protection Wanes Within 1 Year; Boosters Needed
Mpox vaccine protection wanes within 6-12 months, necessitating boosters, according to a study published in the Journal of the American Medical Association. The study, led by Dr. Ai-ris Yonekura Collier, found that vaccine-generated antibodies largely diminish over time, emphasizing the importance of completing the two-dose series and considering booster shots for continued protection.
Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines
Bavarian Nordic A/S announced an agreement with UNICEF to supply 1 million doses of the MVA-BN mpox vaccine for Africa, with all doses available by end of 2024.
Immunization Roundup: FDA Approves FluMist, Updated Novavax COVID-19 Vaccine
FDA approves FluMist for self- or caregiver-administration, Novavax updates COVID-19 vaccine, GSK reports positive data for co-administered RSV and shingles vaccines, WHO adds MVA-BN mpox vaccine to prequalification list, New England ranks as most vaccinated region, pharmacist education reduces vaccine hesitancy, and Vaxcyte announces positive data for 31-valent pneumococcal conjugate vaccine.
EMA extends mpox jab to youngsters
EMA recommends extending Imvanex vaccine indication to adolescents aged 12-17, based on similar immune response and safety profile to adults, crucial for global mpox outbreak response.
Bavarian Nordic Awarded USD 63 Million from the U.S. Government for Production and ...
Bavarian Nordic receives $63M order from BARDA to replenish bulk vaccine inventory and produce 1M freeze-dried JYNNEOS® doses for U.S. smallpox/mpox preparedness, with bulk production in 2025 and freeze-dried deliveries in 2026.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath